Study identifier:H8O-IT-B014
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
EBIRIOS - Exenatide and Basal Insulins Use in the Real Setting: an Italian Observational Study in Patients with Type 2 Diabetes and Secondary Failure of Oral Antihyperglycemic Treatment
Type 2 Diabetes Mellitus
-
No
exenatide, basal insulin
All
888
Observational
18 Years +
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Mar 2015 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
Eli Lilly and Company
No locations available
Arms | Assigned Interventions |
---|---|
exenatide The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with exenatide. | Drug: exenatide subcutaneous injection, 5mcg or 10mcg, twice a day Other Name: BYETTA |
basal insulin The targeted population consists of adult patients with type 2 Diabetes Mellitus unable to achieve the desired level of glycemic control while using oral anti-hyperglycemic agents and who initiate treatment with basal insulin. | Drug: basal insulin subcutaneous injection, dosing according to physician's clinical judgment |